EV-301 trial: survival advantage of Enfortumab vedotin in patients with previously treated advanced urothelial cancer
Results from the phase 3 EV-301 trial were presented at 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ), and published in The New England Journal of Medicine ( N ...
read article